Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pelacarsen in Mild Hepatic Impairment
NCT05026996Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelacarsen in Hyperlipoproteinemia a and cardiovascular disease (CVD) (2 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration at Day 60, Area Under the Curve to Last Quantifiable Concentration at Day 60 and 1 more. Started Nov 2021; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia acardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05026996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026996.